Natera Inc
NASDAQ:NTRA

Watchlist Manager
Natera Inc Logo
Natera Inc
NASDAQ:NTRA
Watchlist
Price: 160.325 USD -0.96% Market Closed
Market Cap: 21.2B USD
Have any thoughts about
Natera Inc?
Write Note

Natera Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Natera Inc
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Natera Inc
NASDAQ:NTRA
Accounts Receivables
$306.9m
CAGR 3-Years
41%
CAGR 5-Years
39%
CAGR 10-Years
46%
Abbvie Inc
NYSE:ABBV
Accounts Receivables
$11.5B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Receivables
$4.6B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Accounts Receivables
$7.3B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Receivables
$1.8B
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Receivables
$6.1B
CAGR 3-Years
4%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Natera Inc
Glance View

Market Cap
19.9B USD
Industry
Biotechnology
Economic Moat
Narrow

In the dynamic world of biotechnology, Natera Inc. stands out as a leader in genetic testing and diagnostics. Founded with the vision of transforming how we understand our genetic blueprint, Natera has grown into a significant player, leveraging advanced molecular biology to decode human DNA with remarkable precision. The company's flagship technology, a proprietary cell-free DNA platform, underpins an array of genetic tests that cater to diverse needs in the fields of oncology, women's health, and organ health. Through this technology, Natera offers prenatal screening tests like Panorama, which can detect chromosomal abnormalities early in pregnancy, providing crucial insights for expectant parents. Additionally, the company's oncology solutions, such as Signatera, assist in tailoring personalized cancer treatment regimens by detecting minimal residual disease, thereby offering oncologists a powerful tool for disease management. Financially, Natera sustains its operations through a robust business model that combines direct billing and reimbursements from insurance providers, alongside partnerships with healthcare institutions. By offering innovative testing solutions, Natera generates revenue through test processing fees and related services. The company's growth is fueled by its investments in research and development, constantly pushing the boundaries to enhance test accuracy and expand into new markets. This strategic focus has not only broadened its portfolio but also fortified its ties with healthcare professionals and institutions worldwide. In navigating the complex landscape of genetic science, Natera continues to play a pivotal role in advancing personalized medicine, positioning itself as a linchpin in the future of healthcare diagnostics.

NTRA Intrinsic Value
55.819 USD
Overvaluation 65%
Intrinsic Value
Price

See Also

What is Natera Inc's Accounts Receivables?
Accounts Receivables
306.9m USD

Based on the financial report for Sep 30, 2024, Natera Inc's Accounts Receivables amounts to 306.9m USD.

What is Natera Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
46%

Over the last year, the Accounts Receivables growth was 20%. The average annual Accounts Receivables growth rates for Natera Inc have been 41% over the past three years , 39% over the past five years , and 46% over the past ten years .

Back to Top